211308-79-1

Usage

Uses

Used in Pharmaceutical and Agrochemical Synthesis:
2-Amino-3-iodo-5-methylpyridine is used as a key intermediate in the synthesis of pharmaceutical and agrochemical products. Its unique structure and reactivity enable the creation of various biologically active compounds, contributing to the development of new drugs and agrochemicals.
Used in Organic Chemistry Research:
In the field of organic chemistry research, 2-Amino-3-iodo-5-methylpyridine is utilized as a valuable building block for the synthesis of complex organic molecules. Its versatility and reactivity in organic synthesis make it an essential component in the development of novel chemical substances and the exploration of new synthetic pathways.
Used in Medicinal Chemistry and Drug Discovery:
2-Amino-3-iodo-5-methylpyridine is employed as a crucial intermediate in medicinal chemistry and drug discovery. Its unique structure and reactivity allow for the design and synthesis of new drug candidates with potential therapeutic applications. Its role in the creation of biologically active compounds makes it a promising candidate for the development of innovative pharmaceuticals.

InChI:InChI=1/C6H7IN2/c1-4-2-5(7)6(8)9-3-4/h2-3H,1H3,(H2,8,9)

Upstream product

• 1603-41-4 (5-methyl-pyridin-2-yl)amine 

Downstream Products

• 847446-54-2 8-iodo-6-methyl-2-(4-fluorophenyl)imidazo[1,2-a]pyridine 
• 500903-95-7 5-methyl-3-[2-(trimethylsilyl)ethynyl]pyridin-2-ylamine 
• 955942-40-2 8-iodo-6-methylimidazo[1,2-a]pyridine 
• 824-52-2 5-methyl-1H-pyrrolo[2,3-b]pyridine 
• 863479-77-0 2-amino-5-methyl-3-ethynylpyridine 
• 59782-91-1 2-chloro-3-iodo-5-methylpyridine 

Relevant academic research and scientific papers

Synthesis, radiolabeling and preliminary in vivo evaluation of multimodal radiotracers for PET imaging and targeted radionuclide therapy of pigmented melanoma

Melanin pigment represents an attractive target to address specific treatment to melanoma cells, such as cytotoxic radionuclides. However, less than half of the patients have pigmented metastases. Hence, specific marker is required to stratify this patient population before proceeding with melanin-targeted radionuclide therapy. In such a context, we developed fluorinated analogues of a previously studied melanin-targeting ligand, N-(2-diethylaminoethyl)-6-iodoquinoxaline-2-carboxamide (ICF01012). These latter can be labeled either with 18F or 131I/125I for positron emission tomography imaging (melanin-positive patient selection) and targeted radionuclide therapy purposes. Here we describe the syntheses, radiosyntheses and preclinical evaluations on melanoma-bearing mice model of several iodo- and fluoro(hetero)aromatic derivatives of the ICF01012 scaffold. After preliminary planar gamma scintigraphic and positron emission tomography imaging evaluations, [125I]- and [18F]-N-[2-(diethylamino)ethyl]-4-fluoro-3-iodobenzamides ([125I]4, [18F]4) were found to be chemically and biologically stable with quite similar tumor uptakes at 1 h p.i. (9.7 ± 2.6% ID/g and 6.8 ± 1.9% ID/g, respectively).

SUBSTITUTED PYRROLOPYRIDINES

There are provided novel compounds of formula (I) wherein R1, R2 and R3 are as defined in the specification and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the kinase Itk.